Researchers develop highly sensitive blood test for cancer
Researchers have developed a new way of analysing cancer patients’ blood for evidence of the disease that could be up to ten times more sensitive than previous methods.
Read More
Tag: mutation
Trial success for Lynparza in prostate cancer
The treatment is the only PARP inhibitor with positive Phase III results in four different cancer types – ovarian, breast, pancreatic and prostate.
Read More
Scientists discover mutation that causes PARP inhibitor resistance
Scientists have made a major discovery having identified a mutation that gives cancer cells resistance to AstraZeneca’s Lynparza and other PARP inhibitors.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
